These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1614055)

  • 1. Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis.
    Vasilakakis DM; D'Haese PC; Lamberts LV; Lemoniatou E; Digenis PN; De Broe ME
    Kidney Int; 1992 May; 41(5):1400-7. PubMed ID: 1614055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.
    Menéndez-Fraga P; Fernández-Martín JL; Blanco-González E; Cannata-Andía JB
    Clin Chem; 1998 Jun; 44(6 Pt 1):1262-8. PubMed ID: 9625051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients.
    Andriani M; Nordio M; Saporiti E
    Nephron; 1996; 72(2):218-24. PubMed ID: 8684530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferoxamine and coated charcoal hemoperfusion to remove aluminum in dialysis patients.
    McCarthy JT; Milliner DS; Schmidt DF; Schniepp BJ; Kurtz SB; Johnson WJ
    Kidney Int; 1988 Dec; 34(6):804-8. PubMed ID: 3210542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of aluminoxamine and ferrioxamine in plasma by high performance liquid chromatography.
    Hughes H; Hagen LE; Cameron EC; Sutton RA
    Clin Chim Acta; 1986 May; 157(1):115-20. PubMed ID: 3719992
    [No Abstract]   [Full Text] [Related]  

  • 6. Accelerated removal of deferoxamine mesylate-chelated aluminum by charcoal hemoperfusion in hemodialysis patients.
    Delmez J; Weerts C; Lewis-Finch J; Windus D; Slatopolsky E
    Am J Kidney Dis; 1989 Apr; 13(4):308-11. PubMed ID: 2705449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aluminum removal with hemodialysis, hemofiltration and charcoal hemoperfusion in uremic patients after desferrioxamine infusion. A comparison of efficiency.
    Weiss LG; Danielson BG; Fellström B; Wikström B
    Nephron; 1989; 51(3):325-9. PubMed ID: 2918944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
    Klemm A; Sperschneider H; Winnefeld K; Günther K; Stein G
    Clin Nephrol; 1997 Feb; 47(2):133-4. PubMed ID: 9049466
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers.
    Molitoris BA; Alfrey AC; Alfrey PS; Miller NL
    Kidney Int; 1988 Jul; 34(1):98-101. PubMed ID: 3172641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of aluminoxamine and feroxamine chelates in dialysis patients.
    Canavese C; Gurioli L; D'Amicone M; Cardelli R; Caligaris F; Bongiorno P; Arnaud A; Mattiello G; Marchiori M
    Nephron; 1992; 60(4):411-7. PubMed ID: 1584315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients.
    Verpooten GA; D'Haese PC; Boelaert JR; Becaus I; Lamberts LV; De Broe ME
    Nephrol Dial Transplant; 1992; 7(9):931-8. PubMed ID: 1328941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis.
    Chang TM; Barre P
    Lancet; 1983 Nov; 2(8358):1051-3. PubMed ID: 6138600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration.
    Canteros-Picotto A; Fernández-Martín JL; Cannata-Andía JB
    Am J Kidney Dis; 2000 Nov; 36(5):969-75. PubMed ID: 11054353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary and biliary excretion of aluminoxamine and ferrioxamine in dogs with various renal function.
    D'Haese PC; Lamberts LV; Verpooten GA; Vaneerdeweg W; Jurgens A; Arakelian S; Babloyan A; Digenis P; Tjalma W; De Broe ME
    Kidney Int; 1994 Jan; 45(1):76-84. PubMed ID: 8127024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion.
    Pizzella KM; Moore MC; Schultz RW; Walshe J; Schentag JJ
    Ther Drug Monit; 1980; 2(3):273-81. PubMed ID: 7222181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect measurement of desferrioxamine and its chelated compounds aluminoxamine and ferrioxamine by Zeeman atomic absorption spectrometry.
    D'Haese PC; Lamberts LV; De Broe ME
    Clin Chem; 1989 May; 35(5):884-7. PubMed ID: 2720988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis.
    Allain P; Mauras Y; Chaleil D; Simon P; Ang KS; Cam G; Le Mignon L; Simon M
    Br J Clin Pharmacol; 1987 Aug; 24(2):207-12. PubMed ID: 3620295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodialysis-related porphyria cutanea tarda--treatment failure with charcoal hemoperfusion.
    McColl KE; Simpson K; Laiwah AY; Thompson GG; McDougall A; Moore MR
    Photodermatol; 1986 Jun; 3(3):169-73. PubMed ID: 3529056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia.
    Winchester JF; Ratcliffe JG; Carlyle E; Kennedy AC
    Kidney Int; 1978 Jul; 14(1):74-81. PubMed ID: 682427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.